SCHEDULE 13D: Baker Bros. Advisors Bolsters Stake in Replimune Group, Secures Board Representation

Baker Bros. Advisors LP and its affiliates have increased their beneficial ownership in Replimune Group, Inc. to 14.3% and secured a board seat with the appointment of Michael Goller.

Summary

• Baker Bros. Advisors LP, Baker Bros. Advisors (GP) LLC, Julian C. Baker, and Felix J. Baker (collectively, the "Reporting Persons") beneficially own an aggregate of 11,045,336 shares of Replimune Group, Inc. Common Stock.
• This ownership represents 14.3% of the Issuer's outstanding Common Stock, based on 77,014,781 shares outstanding as of February 7, 2025.
• The securities were acquired through working capital of the Funds (667, L.P. and Baker Brothers Life Sciences, L.P.) via open market purchases, transactions with underwriters, and a private placement directly with the Issuer, totaling approximately $337,883,672.
• The holdings include 4,542,391 2020/2022 $0.0001 Prefunded Warrants, 3,846,184 2024 $0.0001 Prefunded Warrants, and 5,669,578 $0.001 Prefunded Warrants, which are currently not exercisable due to beneficial ownership limitations (4.99% or 9.99%).
• On March 5, 2025, Replimune's Board of Directors increased its size from nine to ten members and appointed Michael Goller, a full-time employee of Baker Bros. Advisors, as a Class I director.
• In connection with his appointment, Michael Goller was granted 64,000 stock options at an exercise price of $12.29 per share, vesting over time until March 5, 2035.
• The Funds entered into a Registration Rights Agreement with Replimune on March 5, 2025, granting them certain resale registration rights for their shares, including rights to underwritten public offerings.

Sentiment

Score: 8

Explanation: The document indicates a strong positive sentiment due to a major, specialized investor increasing its stake and gaining board representation, signaling confidence and potential strategic alignment.

Positives

• A significant institutional investor, Baker Bros. Advisors, has increased its stake and secured a board seat, indicating strong confidence in Replimune Group, Inc.'s future.
• The appointment of Michael Goller to the Board provides Baker Bros. with direct influence and oversight, potentially aligning strategic decisions with long-term shareholder value.
• The Registration Rights Agreement provides the Funds with a clear path for future liquidity of their substantial holdings, which could be beneficial for the company by facilitating orderly market transactions.

Negatives

• A significant portion of Baker Bros.'s holdings are in prefunded warrants that are currently not exercisable due to beneficial ownership limitations (4.99% or 9.99%), restricting immediate conversion into common stock.

Risks

• The beneficial ownership limitations on the prefunded warrants mean that Baker Bros. cannot immediately exercise these warrants to increase their direct common stock holdings beyond the specified percentages, which could limit their flexibility or influence in certain scenarios.

Future Outlook

The Reporting Persons intend to hold securities for investment purposes and may purchase additional securities or dispose of existing holdings based on their ongoing assessment of various factors, including the Issuer's business prospects, economic conditions, and market conditions. They may also engage in discussions with the Issuer's management and other investors, potentially including suggestions regarding financing or further acquisitions/dispositions of securities.

Industry Context

This filing highlights continued significant investor interest in the biotechnology sector, specifically in Replimune Group, Inc., a company focused on oncology. Baker Bros. Advisors is a prominent investment firm specializing in life sciences, and their increased stake and board representation signal a strong vote of confidence in Replimune's strategic direction and potential within the competitive biotech landscape.

Management Changes

Corporate Governance

Related Party Transactions

• Michael Goller, a full-time employee of Baker Bros. Advisors, was appointed to Replimune's Board of Directors and granted 64,000 stock options. The pecuniary interest in any compensation received by Michael Goller for his service as a director is entitled to the Funds (Baker Bros. entities), as per their policy.

Stakeholder Impact

• Shareholders: The increased stake and board representation by a prominent life sciences investor like Baker Bros. Advisors could be viewed positively, signaling confidence and potentially leading to enhanced strategic direction and governance. The registration rights agreement provides a mechanism for future liquidity for a large block of shares.
• Management: The addition of a Baker Bros. representative to the board introduces a new voice and perspective, potentially influencing strategic discussions and corporate decision-making.
• Employees: No direct impact mentioned, but strategic shifts influenced by the new board member could indirectly affect employees.

Next Steps

• Michael Goller will serve as a Class I director until Replimune's 2025 annual general meeting of shareholders.
• The Reporting Persons may purchase additional securities or dispose of existing securities in the future.
• The Reporting Persons may engage in discussions with Replimune's management and other investors regarding various matters, including financing.

Key Dates

Recommendation

Keywords

Replimune Group, Baker Bros. Advisors, Schedule 13D, beneficial ownership, biotechnology, pharmaceutical, oncology, warrants, board appointment, investment, SEC filing